https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34560 Wed 27 Mar 2019 10:17:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33561 Wed 21 Nov 2018 09:47:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8584 Wed 11 Apr 2018 14:17:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33991 4 weeks) cough (KQ 1) are the common etiologies different from those in adults? (KQ 2) Are the common etiologies age or setting dependent, or both? (KQ 3) Is OSA a cause of chronic cough in children? Methods: We used the CHEST Expert Cough Panel's protocol and the American College of Chest Physicians (CHEST) methodological guidelines and Grading of Recommendations Assessment, Development, and Evaluation framework. Data from the systematic reviews in conjunction with patients' values and preferences and the clinical context were used to form recommendations. Delphi methodology was used to obtain consensus. Results: Combining KQs 1 and 2, we found moderate-level evidence from 10 prospective studies that the etiologies of cough in children are different from those in adults and are setting dependent. Data from three studies found that common etiologies of cough in young children were different from those in older children. However, data relating sleep abnormalities to chronic cough in children were found only in case studies. Conclusions: There is moderate-quality evidence that common etiologies of chronic cough in children are different from those in adults and are dependent on age and setting. As there are few data relating OSA and chronic cough in children, the panel suggested that these children should be managed in accordance with pediatric sleep guidelines.]]> Tue 29 Jan 2019 15:55:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48561 Tue 21 Mar 2023 15:45:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40865 12 years of age with a chronic cough due to asthma or NAEB. Eligible studies were identified in MEDLINE, CENTRAL, and SCOPUS and assessed for relevance and quality. Guidelines were developed and voted upon using CHEST guideline methodology. Results: Of the citations reviewed, 3/1,175, 53/656, and 6/134 were identified as being eligible for inclusion in the three systematic reviews, respectively. In contrast to established guidelines for asthma therapies in general and the inclusion in some guidelines for a role of biomarkers of airway inflammation to guide treatment in severe disease, the evidence of specific benefit related to the use of non-invasive biomarkers in patients with chronic cough due to asthma was weak. The best therapeutic option for cough in asthma or NAEB is inhaled corticosteroids followed by leukotriene receptor antagonism. Conclusions: This guideline offers recommendations on the role of non-invasive measurements of airway inflammation and treatment for cough due to asthma or NAEB based on the available literature, and identifies gaps in knowledge and areas for future research.]]> Tue 19 Jul 2022 14:10:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51598 Tue 12 Sep 2023 12:25:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45975 Is there evidence of clinically important treatment effects for non-pharmacological therapies in cough treatment for patients with bronchiectasis?" Populations selected were all patients with bronchiectasis due to CF or non-CF bronchiectasis. The interventions explored were the non-pharmacological airway clearance therapies. The comparison populations included those receiving standard therapy and/or placebo. Clinically important outcomes that were explored were exacerbation rates, quality of life, hospitalizations, and mortality. Results: In both CF and non-CF bronchiectasis, there were systematic reviews and overviews of systematic reviews identified. Despite these findings, there were no large randomized controlled trials that explored the impact of airway clearance on exacerbation rates, quality of life, hospitalizations, or mortality. Conclusions: Although the cough panel was not able to make recommendations, they have made consensus-based suggestions and provided direction for future studies to fill the gaps in knowledge.]]> Tue 08 Nov 2022 14:39:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46902  8. Overall, there was no difference in survival or disease progression, regardless of antacid treatment, GORD diagnosis or GORD symptoms. Conclusions: Neither the use of antacid therapy nor the presence of GORD symptoms affects longer term outcomes in IPF patients. This contributes to the increasing evidence that antacid therapy may not be beneficial in IPF patients and that GORD directed therapy should be considered on an individual basis to treat the symptoms of reflux.]]> Tue 06 Dec 2022 16:07:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51437 Tue 05 Sep 2023 17:56:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25793 Thu 27 Jan 2022 15:58:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38607 Thu 18 Nov 2021 10:35:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48859 Thu 13 Apr 2023 09:53:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31318 psychogenic cough has been used to describe cough without obvious medical etiology, which is refractory to medical management and considered to have a psychiatric or psychological basis. However there are limitations in the research into psychogenic cough with limited empirical data on how to define the condition or differentially diagnose it from other forms of chronic cough. The term somatic cough syndrome was introduced by the American College of Chest physicians in 2015 during their revision of the 2006 guideline on psychogenic cough. Psychomorbidity can be present in chronic cough arising from a variety of etiologies and can impact on symptom perception and clinical management of the condition. Psychological symptoms can also improve after effective treatment of the chronic cough. The recently published American College of Chest Physicians cough guidelines recommended replacing the term psychogenic cough with the term somatic cough syndrome in order to be consistent with the Diagnostic Statistical Manual of Mental Disorders, 5^th edition (DSM-5) where the term psychogenic is no longer used. This paper outlines the current evidence regarding psychogenic cough, proposes a model for conceptualising psychological issues in chronic cough and discusses strategies for clinical management of psychological issues in patients with chronic cough.]]> Sat 24 Mar 2018 08:43:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7161 Sat 24 Mar 2018 08:34:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1274 2.5%) was 45% in the wheeze group, which was significantly higher than the control group (9.35%, p = 0.04). Eosinophilic bronchitis was present in two children with cough (20%) and two with chest colds (15%, p > 0.05 versus control). In these groups, eosinophilic bronchitis was not associated with airway hyperresponsiveness (AHR) to hypertonic saline (p > 0.05). Children with cough and chest colds reported greater exposure to environmental tobacco smoke. In conclusion, this community-based survey of children with chronic respiratory symptoms has shown that wheeze is a good discriminator for the presence of eosinophilic bronchitis, and that persistent cough and recurrent chest colds without wheeze should not be considered a variant of asthma. Eosinophilic bronchitis did occur in a significant minority of these "variant asthma" syndromes.]]> Sat 24 Mar 2018 08:32:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14776 Sat 24 Mar 2018 08:26:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12828 G-nitro-L-arginine following blockade of α- and β-adrenoceptors and cholinoceptors causes hypertension, but minor changes, if any, in pulmonary pressures or heart rate. Bronchial flow and conductance, however, fall from a higher resting conductance by approximately 50%, suggesting that, normally, resting bronchial flow conductance is dominated by strong tonic NO vasodilator effects that interact with weaker tonic autonomic vasoconstrictor effects.6. Superimposed (respiratory) behaviours of sighing, sneezing and coughing, which involve negative swings in intrathoracic pressure and the movement of inspired air, evoke large active bronchovascular dilator effects. These appear to be largely NANC in origin and appear to be dependent, in part, on mechanisms associated with NO release. It is postulated that the C-fibre axon reflex using substance P, calcitonin gene-related peptide and neurokinin A may be involved. Vocalization and eructation do not evoke bronchovascular effects.]]> Sat 24 Mar 2018 08:17:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13277 Sat 24 Mar 2018 08:15:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21447 Sat 24 Mar 2018 08:05:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19955 Sat 24 Mar 2018 07:58:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17992 Sat 24 Mar 2018 07:56:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29432 Sat 24 Mar 2018 07:39:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29176 Sat 24 Mar 2018 07:35:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25578 Sat 24 Mar 2018 07:35:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4817 Sat 24 Mar 2018 07:18:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46104 adj = 9.6, 95% CI: 1.8–50.1) and the presence of Haemophilus influenzae in the BAL (OR_adj = 5.1, 95% CI: 1.4–19.1). Clinician-diagnosed asthma at final follow-up was present in 27.1% of children with PBB. A significant BDR (FEV₁ improvement >12%) was obtained in 63.5% of the children who underwent reversibility testing. Positive allergen-specific IgE (OR_adj = 14.8, 95% CI: 2.2–100.8) at baseline and bronchomalacia (OR_adj = 5.9, 95% CI: 1.2–29.7) were significant predictors of asthma diagnosis. Spirometry parameters were in the normal range. Conclusion: As a significant proportion of children with PBB have ongoing symptoms at 5 years, and outcomes include bronchiectasis and asthma, they should be carefully followed up clinically. Defining biomarkers, endotypes and mechanistic studies elucidating the different outcomes are now required.]]> Mon 21 Nov 2022 09:17:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47390 Mon 16 Jan 2023 15:52:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36789 Mon 06 Jul 2020 11:38:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47886 Mon 06 Feb 2023 11:33:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49491 4-weeks duration) and without underlying lung disease: (1) who do not havegastrointestinal GER symptoms, should empirical treatment for GERD be used? (2) withgastrointestinal GER symptoms, does treatment for GERD resolve the cough? (3) with orwithout gastrointestinal GER symptoms, what GER-based therapies should be used and forhow long? (4) if GERD is suspected as the cause, what investigations and diagnostic criteriabest determine GERD as the cause of the cough?METHODS:We used the CHEST Expert Cough Panel’s protocol and American College ofChest Physicians (CHEST) methodological guidelines and GRADE (Grading of Recom-mendations Assessment, Development and Evaluation) framework. Delphi methodology wasused to obtain consensus.RESULTS:Few randomized controlled trials addressed thefirst two questions and noneaddressed the other two. The single meta-analysis (two randomized controlled trials)showed no significant difference between the groups (any intervention for GERDvs placebo for cough resolution; OR, 1.14; 95% CI, 0.45-2.93;P¼.78). Proton pumpinhibitors (vs placebo) caused increased serious adverse events. Qualitative data fromexisting CHEST cough systematic reviews were consistent with two international GERDguidelines.CONCLUSIONS:The panelists endorsed that: (1) treatment(s) for GERD should not be usedwhen there are no clinical features of GERD; and (2) pediatric GERD guidelines should beused to guide treatment and investigations.]]> Fri 19 May 2023 09:55:59 AEST ]]>